Notopedia is a nonprofit organization with a mission to provide free learning support to all. Click here to donate or volunteer  

Notopedia has a mission to provide free learning support. Click here to donate or volunteer.

Serum Institute to manufacture NOVAVAX Vaccine

fsjd_icon1 ADMISSIONS

save
banner
Serum Institute to manufacture NOVAVAX Vaccine
fsjd_icon1 ADMISSIONS

Description

Serum Institute to manufacture NOVAVAX Vaccine

Date -15th Jun 2021

US biotechnology company NOVAVAX announced on June 14, 2021 that its COVID-19 vaccine provides 100% protection against moderate to severe disease symptoms and has shown an overall 90.4% efficacy in phase 3 trials. Speaking about the results of clinical trials, the President and Chief Executive Officer NOVAVAX CEO Stanley Eric said NOVAVAX is now one step closer to addressing the urgent and ongoing public health need for additional vaccines.

  • The results confirm that the NOVAVAX vaccine is extremely effective and provides complete protection against both moderate and severe COVID-19 infections.
  • The Maryland-based company said it intends to file for regulatory approval by the third quarter of 2021.

Click on the image to view the official tweet

The NOVAVAX COVID-19 vaccine, NVX-CoV2373, may be a candidate for protein vaccines. It is based on the genetic sequence of the primary strain of SARS-CoV-2, the virus that caused COVID-19. In a Phase 3 trial, NOVAVAX enrolled 29,960 participants at 119 centers in the United States and Mexico to evaluate the safety, efficacy, and immunogenicity of the vaccine. Emphasis has also been placed on recruiting a representative population from the communities and demographics most affected by COVID-19.

In terms of vaccination rates, these countries lag significantly behind the industrialized nations of the Group of Seven and other wealthy nations. In terms of doses administered so far, the imbalance between low-income countries and the G7 countries is 73 to one, according to the World Bank.

The Serum Institute will produce the NOVAVAX vaccine

In 2020, NOVAVAX announced an amendment to its existing agreement with the Serum Institute of India under which SII will also produce the antigenic component of NVX-CoV2373, the COVID-19 candidate vaccine from NOVAVAX.

For more Updates and Information - Click here 

For access to more than 10,000 Colleges - Click here

For Latest Sarkari Jobs - Click here

For Comprehensive Preparation of Competitive Exams - Click here

For School Studies and Exams Preparation across Eight Boards - Click here

The Notopedia Bulletin Board

News about the latest admissions, results, upcoming government jobs, Sarkari exams and many more.

bulletin images
RESULTS

Latest and upcoming results

Explore
bulletin images
ADMISSIONS

Get important alerts

Explore
bulletin images
JOBS

Latest job postings

Explore
bulletin images
SCHOOL

ICSE, CBSE and State Boards

Explore
bulletin images
COLLEGE

Get latest college updates

Explore
bulletin images
EXAM

Latest exam news

Explore
bulletin images
CURRENT AFFAIRS

Latest Current Affairs

Explore


Request For Material

Close Submit
Submit Material

Close Submit